Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
Sponsor: Memorial Sloan Kettering Cancer Center
Summary
The purpose of this study is to test see the combined effects of the study drug called Humanized 3F8 (Hu3F8) when used with granulocyte-macrophage colony stimulating factor (GM-CSF). Hu3F8 plus GM-CSF could prevent your neuroblastoma from growing, but it could also cause side effects.
Official title: Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin for Consolidation of First Remission of Patients With High-Risk Neuroblastoma: A Phase II Study
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
59
Start Date
2017-01-23
Completion Date
2025-09-29
Last Updated
2026-10-30
Healthy Volunteers
No
Conditions
Interventions
Hu3F8
Day 1: hu3F8 infused iv over \~30 to 90 minutes. Day 3: hu3F8 infused iv over \~30 to 90 minutes. Day 5: hu3F8 infused iv over \~30 to 90 minutes.
GM-CSF
Days -4 to 0: GM-CSF 250 mcg/m2/day, subcutaneously. Days 1 to 5: GM-CSF 500 mcg/m2/day, subcutaneously.
Isotretinoin
Isotretinoin is administered at 160 mg/m2/d, divided into two doses, x14 days.
Locations (1)
Memorial Sloan Kettering Cancer Center
New York, New York, United States